Applied Therapeutics Inc (APLT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Applied Therapeutics Inc (APLT) has a cash flow conversion efficiency ratio of 32.800x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.40 Million) by net assets ($-561.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Applied Therapeutics Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Applied Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Applied Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Applied Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Applied Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Innodep Inc.
KQ:303530
|
-0.187x |
|
Scienture Holdings, Inc.
NASDAQ:SCNX
|
0.000x |
|
GigaMedia Limited
F:GIFN
|
N/A |
|
Leyand International Tbk
JK:LAPD
|
0.140x |
|
BBI Development S.A.
WAR:BBD
|
0.056x |
|
Resonance Health Ltd
AU:RHT
|
0.016x |
|
iRobot Corporation
NASDAQ:IRBT
|
1.770x |
|
Alton Sports Co.Ltd
KQ:123750
|
0.190x |
Annual Cash Flow Conversion Efficiency for Applied Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Applied Therapeutics Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see Applied Therapeutics Inc (APLT) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $57.01 Million | $-84.31 Million | -1.479x | -145.96% |
| 2023-12-31 | $-17.15 Million | $-55.17 Million | 3.218x | +116.73% |
| 2022-12-31 | $4.06 Million | $-78.09 Million | -19.230x | -1225.53% |
| 2021-12-31 | $62.54 Million | $-90.73 Million | -1.451x | -51.99% |
| 2020-12-31 | $81.94 Million | $-78.21 Million | -0.954x | +14.28% |
| 2019-12-31 | $32.61 Million | $-36.31 Million | -1.113x | -57.51% |
| 2018-12-31 | $15.82 Million | $-11.18 Million | -0.707x | -187.64% |
| 2017-12-31 | $-3.96 Million | $-3.19 Million | 0.807x | -- |
About Applied Therapeutics Inc
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric cli… Read more